Clinical trial

Anlotinib Combined With Docetaxel Versus Docetaxel for Previous Treated Advanced NSCLC

NCT03726736

StatusUNKNOWN

Study typeINTERVENTIONAL

Start date2018-12-21

PhasePHASE1 / PHASE2

Study timeline

Study start (actual)2018-12-21Date precision: day

Registry last updated2019-06-07

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

Non-small Cell Lung Cancerunresolved

Interventions

Anlotinib combined DocetaxelDRUG

DocetaxelDRUG · verified · RxNorm: docetaxel

Sponsors & collaborators

Yong Fanglead sponsor

Zhejiang Provincial People's Hospitalcollaborator

Zhejiang Cancer Hospitalcollaborator

Ningbo No. 1 Hospitalcollaborator

Ningbo No.2 Hospitalcollaborator

Affiliated Hospital of Jiaxing Universitycollaborator

Huzhou Central Hospitalcollaborator

Mapped research locations

HangzhouZhejiang, China1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03726736 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.